# EDGAR Filing Document

**Accession Number:** 0002042347
**File Stem:** 0001193125-26-186943
**Filing Date:** 2026-4
**Character Count:** 4707
**Document Hash:** 9f81c8251f9c382c097fa32739717de7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-186943.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001193125-26-186943

**CONFORMED SUBMISSION TYPE**: 8-A12B

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Seaport Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0002042347
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 992235719
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-A12B
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43254
- **FILM NUMBER:** 26907618

**BUSINESS ADDRESS:**
- **STREET 1:** 6 TIDE STREET
- **STREET 2:** SUITE 400
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** 617-807-4062

**MAIL ADDRESS:**
- **STREET 1:** 6 TIDE STREET
- **STREET 2:** SUITE 400
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES** 

**PURSUANT TO SECTION 12(b) OR (g) OF** 

**THE SECURITIES EXCHANGE ACT OF 1934** 

## Seaport Therapeutics, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **99-2235719** |
| **(State of incorporation or organization)** | **(I.R.S. Employer Identification No.)** |
| **Seaport Therapeutics, Inc.**<br> **101 Seaport Blvd., Floor 12**<br> **Boston, Massachusetts** | **02210** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Securities to be registered pursuant to Section 12(b) of the Act:** 

---

| | |
|:---|:---|
| **Title of each class<br>to be so registered** | **Name of each exchange on which<br>each class is to be registered** |
| **Common Stock, par value $0.0001 per share** | **The Nasdaq Stock Market LLC** |

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

**Securities Act registration statement file or Regulation A offering statement number to which this form relates (if applicable):** 

**333-294976** 

**Securities to be registered pursuant to Section 12(g) of the Act:** 

**None** 

------

**Item 1.** **Description of Registrant's Securities to be Registered.** <br>

For a description of Seaport Therapeutics, Inc.'s (the "Registrant") common stock, par value $0.0001 per share (the "Common Stock"), to be registered hereunder, reference is made to the information set forth under the heading "Description of Capital Stock" in the Registrant's prospectus that constitutes a part of the Registrant's Registration Statement on Form S-1 (File No. 333-294976) initially filed with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), on April 10, 2026, including exhibits, and as amended from time to time (the "Registration Statement"), which information is hereby incorporated by reference. The description of the Common Stock included in any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act that constitutes part of the Registration Statement shall be deemed to be incorporated by reference herein.

**Item 2.** **Exhibits.** <br>

In accordance with the "Instructions as to Exhibits" with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

------

**SIGNATURE** 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SEAPORT THERAPEUTICS, INC.** | **SEAPORT THERAPEUTICS, INC.** |
|  Date: April 28, 2026 | By: | /s/ Daphne Zohar |
|  |  | Daphne Zohar |
|  |  | Chief Executive Officer |

---